GeNeuro Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor GeNeuro te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Biotechs winstgroei	8.1%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Breakeven On The Horizon For GeNeuro SA (EPA:GNRO)

Mar 14

Recent updates

Breakeven On The Horizon For GeNeuro SA (EPA:GNRO)

Mar 14

Analysts Expect Breakeven For GeNeuro SA (EPA:GNRO) Before Long

Nov 28

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat GeNeuro onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

ENXTPA:GNRO - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2023	N/A	-15	-10	-10	N/A
9/30/2023	N/A	-14	-13	-13	N/A
6/30/2023	N/A	-13	-15	-15	N/A
3/31/2023	N/A	-13	-14	-14	N/A
12/31/2022	N/A	-12	-13	-13	N/A
9/30/2022	N/A	-11	N/A	N/A	N/A
6/30/2022	N/A	-9	-6	-6	N/A
3/31/2022	N/A	-8	-6	-6	N/A
12/31/2021	N/A	-7	-7	-7	N/A
9/30/2021	N/A	-8	N/A	N/A	N/A
6/30/2021	N/A	-8	-7	-7	N/A
3/31/2021	N/A	-9	-7	-7	N/A
12/31/2020	N/A	-9	-7	-7	N/A
9/30/2020	N/A	-9	-7	-7	N/A
6/30/2020	N/A	-9	-8	-7	N/A
3/31/2020	N/A	-9	-9	-9	N/A
12/31/2019	N/A	-9	-10	-10	N/A
9/30/2019	0	-10	-12	-12	N/A
6/30/2019	0	-10	-15	-15	N/A
3/31/2019	4	-9	-16	-16	N/A
12/31/2018	7	-8	-18	-18	N/A
9/30/2018	13	-4	-12	-12	N/A
6/30/2018	19	0	-6	-6	N/A
3/31/2018	17	-3	-7	-7	N/A
12/31/2017	15	-6	-8	-8	N/A
9/30/2017	10	-11	N/A	-13	N/A
6/30/2017	6	-16	N/A	-19	N/A
3/31/2017	6	-15	N/A	-16	N/A
12/31/2016	6	-14	N/A	-14	N/A
9/30/2016	6	-11	N/A	-4	N/A
6/30/2016	5	-9	N/A	6	N/A
3/31/2016	4	-7	N/A	9	N/A
12/31/2015	3	-4	N/A	12	N/A
9/30/2015	5	-1	N/A	8	N/A
6/30/2015	8	2	N/A	4	N/A
3/31/2015	8	2	N/A	3	N/A
12/31/2014	7	2	N/A	3	N/A
12/31/2013	0	-3	N/A	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van GNRO boven de spaarquote ( 1.2% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van GNRO naar verwachting sneller zal groeien dan de markt French

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van GNRO naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van GNRO naar verwachting sneller zal groeien dan de markt French.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van GNRO naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van GNRO naar verwachting over 3 jaar hoog zal zijn

GeNeuro Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 49% to €2.05

Forecast to breakeven in 2024

Price target decreased to €5.55

Price target decreased to €5.55

Consensus forecasts updated

Breakeven On The Horizon For GeNeuro SA (EPA:GNRO)

Recent updates

Price target decreased by 49% to €2.05

GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome

GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024

Geneuro SA Announces Appointments of Board of Directors

New minor risk - Shareholder dilution

GeNeuro SA has completed a Follow-on Equity Offering in the amount of €4.900246 million.

Geneuro S.A. Recommends Continuing the Trial Evaluating Temelimab in Long Covid Without Modifications

New major risk - Revenue and earnings growth

Forecast to breakeven in 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

GeNeuro Announces Completion of Recruitment of its Long-COVID Phase 2 Trial and Confirms Top-Line Results for June 2024

New major risk - Negative shareholders equity

New minor risk - Share price stability

GeNeuro SA Announces Recent Study Demonstrates the Strong Link Between SARS-CoV-2 Infection and HERV-W Activation in Hospitalized Psychotic Patients

GeNeuro SA to Report First Half, 2023 Results on Sep 29, 2023

New minor risk - Profitability

Insufficient new directors

GeNeuro SA, Annual General Meeting, Jun 14, 2023

Price target decreased to €5.55

Insufficient new directors

GeNeuro SA Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-Covid Assessing Temelimab

Geneuro’S Protect-Ms Phase 2 Trial Data, Presented At the Ectrims 2022 Congress in Amsterdam, Confirms Synergistic Neuroprotective Potential of Temelimab in Ms

GeNeuro Will Present Phase IIb Safety and Efficacy Data on Temelimab from its ProTEct-MS Study at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis

Geneuro Is Granted Authorization by the Swiss Health Authority to Initiate A Phase II Study Evaluating Temelimab in Patients with Severe Neuropsychiatric Post-Covid Syndromes

Price target decreased to €5.55

Insufficient new directors

GeNeuro SA, Annual General Meeting, May 31, 2022

GeNeuro and Fondamental Foundation Announce the First Results of the Collaboration for the Development of Diagnostic and Therapeutic Options for Patients with Post-Covid Neuropsychiatric Syndromes

GeNeuro Announces the Completion of Its ProTEct-MS Study and Confirms the March Timeline for Top-line Results

Geneuro Sa unveils Additional Results from the Preclinical Research Program in Amyotrophic Lateral Sclerosis (Als) Developed in Partnership with the National Institute of Neurological Disorders and Stroke

Geneuro Receives EUR 6.4 Million in Funding from the Swiss Government for the Development of Temelimab Against Long-Covid

GeNeuro Announces First Patient Having Finished the ProTEct-MS Study at the Karolinska Institutet’s Academic Specialist Center Has Entered the Study Extension

GeNeuro Announces the Publication in Multiple Sclerosis of Results From CHANGE-MS and ANGEL-MS Studies

Geneuro Presents Data Supporting Pathogenic Role of an Endogenous Retroviral Protein (HERV-W ENV) in Post-Covid Neuropsychiatric Syndrome

Consensus forecasts updated

Breakeven On The Horizon For GeNeuro SA (EPA:GNRO)

GeNeuro SA Announces Independent Drug Safety Monitoring Board (Dsmb) Has Concluded the Phase 2 Trial of Temelimab in Ms Patients

GeNeuro Completes Patient Recruitment in Temelimab Phase 2 Multiple Sclerosis Trial at the Karolinska Institutet’s Academic Specialist Center (ASC)

New 90-day high: €3.92

New 90-day low: €2.60

Analysts Expect Breakeven For GeNeuro SA (EPA:GNRO) Before Long

New 90-day low: €2.62

New 90-day low: €3.00

New 90-day low: €3.01

GeNeuro SA Announces Management Changes

GeNeuro SA to Report First Half, 2020 Results on Sep 29, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven